vs
Side-by-side financial comparison of Axon Enterprise (AXON) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Axon Enterprise is the larger business by last-quarter revenue ($796.7M vs $783.7M, roughly 1.0× Insulet Corporation). Insulet Corporation runs the higher net margin — 13.0% vs 0.3%, a 12.6% gap on every dollar of revenue. On growth, Axon Enterprise posted the faster year-over-year revenue change (38.9% vs 31.2%). Axon Enterprise produced more free cash flow last quarter ($155.4M vs $48.2M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 31.5%).
Axon Enterprise, Inc. is an American company based in Scottsdale, Arizona, that develops weapons and technology products for military, law enforcement, and civilians.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
AXON vs PODD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $796.7M | $783.7M |
| Net Profit | $2.7M | $101.6M |
| Gross Margin | 57.9% | 72.6% |
| Operating Margin | -6.3% | 18.7% |
| Net Margin | 0.3% | 13.0% |
| Revenue YoY | 38.9% | 31.2% |
| Net Profit YoY | -98.0% | 0.9% |
| EPS (diluted) | $0.02 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $796.7M | $783.7M | ||
| Q3 25 | $710.6M | $706.3M | ||
| Q2 25 | $668.5M | $649.1M | ||
| Q1 25 | $603.6M | $569.0M | ||
| Q4 24 | $573.4M | $597.5M | ||
| Q3 24 | $544.3M | $543.9M | ||
| Q2 24 | $504.1M | $488.5M | ||
| Q1 24 | $460.7M | $441.7M |
| Q4 25 | $2.7M | $101.6M | ||
| Q3 25 | $-2.2M | $87.6M | ||
| Q2 25 | $36.1M | $22.5M | ||
| Q1 25 | $88.0M | $35.4M | ||
| Q4 24 | $136.0M | $100.7M | ||
| Q3 24 | $67.0M | $77.5M | ||
| Q2 24 | $40.8M | $188.6M | ||
| Q1 24 | $133.2M | $51.5M |
| Q4 25 | 57.9% | 72.6% | ||
| Q3 25 | 60.1% | 72.2% | ||
| Q2 25 | 60.4% | 69.7% | ||
| Q1 25 | 60.6% | 71.9% | ||
| Q4 24 | 60.5% | 72.1% | ||
| Q3 24 | 60.8% | 69.3% | ||
| Q2 24 | 60.3% | 67.7% | ||
| Q1 24 | 56.4% | 69.5% |
| Q4 25 | -6.3% | 18.7% | ||
| Q3 25 | -0.3% | 16.7% | ||
| Q2 25 | -0.2% | 18.7% | ||
| Q1 25 | -1.5% | 15.6% | ||
| Q4 24 | -2.6% | 18.3% | ||
| Q3 24 | 4.4% | 16.2% | ||
| Q2 24 | 6.5% | 11.2% | ||
| Q1 24 | 3.5% | 12.9% |
| Q4 25 | 0.3% | 13.0% | ||
| Q3 25 | -0.3% | 12.4% | ||
| Q2 25 | 5.4% | 3.5% | ||
| Q1 25 | 14.6% | 6.2% | ||
| Q4 24 | 23.7% | 16.9% | ||
| Q3 24 | 12.3% | 14.2% | ||
| Q2 24 | 8.1% | 38.6% | ||
| Q1 24 | 28.9% | 11.7% |
| Q4 25 | $0.02 | $1.42 | ||
| Q3 25 | $-0.03 | $1.24 | ||
| Q2 25 | $0.44 | $0.32 | ||
| Q1 25 | $1.08 | $0.50 | ||
| Q4 24 | $1.68 | $1.38 | ||
| Q3 24 | $0.86 | $1.08 | ||
| Q2 24 | $0.53 | $2.59 | ||
| Q1 24 | $1.73 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | — |
| Total DebtLower is stronger | $1.8B | $930.8M |
| Stockholders' EquityBook value | $3.2B | $1.5B |
| Total Assets | $7.0B | $3.2B |
| Debt / EquityLower = less leverage | 0.56× | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $788.1M | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $968.9M | — | ||
| Q1 24 | $964.1M | — |
| Q4 25 | $1.8B | $930.8M | ||
| Q3 25 | $2.0B | $934.9M | ||
| Q2 25 | $2.0B | $939.0M | ||
| Q1 25 | $2.0B | $1.6B | ||
| Q4 24 | $680.3M | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
| Q4 25 | $3.2B | $1.5B | ||
| Q3 25 | $3.0B | $1.4B | ||
| Q2 25 | $2.7B | $1.5B | ||
| Q1 25 | $2.6B | $1.3B | ||
| Q4 24 | $2.3B | $1.2B | ||
| Q3 24 | $2.1B | $1.1B | ||
| Q2 24 | $1.9B | $998.4M | ||
| Q1 24 | $1.8B | $790.7M |
| Q4 25 | $7.0B | $3.2B | ||
| Q3 25 | $6.7B | $3.0B | ||
| Q2 25 | $6.2B | $3.5B | ||
| Q1 25 | $6.1B | $3.5B | ||
| Q4 24 | $4.5B | $3.1B | ||
| Q3 24 | $4.0B | $3.0B | ||
| Q2 24 | $3.7B | $2.9B | ||
| Q1 24 | $3.6B | $2.6B |
| Q4 25 | 0.56× | 0.61× | ||
| Q3 25 | 0.66× | 0.68× | ||
| Q2 25 | 0.73× | 0.64× | ||
| Q1 25 | 0.79× | 1.21× | ||
| Q4 24 | 0.29× | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 1.72× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $217.2M | $183.3M |
| Free Cash FlowOCF − Capex | $155.4M | $48.2M |
| FCF MarginFCF / Revenue | 19.5% | 6.2% |
| Capex IntensityCapex / Revenue | 7.8% | 17.2% |
| Cash ConversionOCF / Net Profit | 79.14× | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | $75.1M | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $217.2M | $183.3M | ||
| Q3 25 | $60.0M | $125.7M | ||
| Q2 25 | $-91.7M | $196.5M | ||
| Q1 25 | $25.8M | $63.8M | ||
| Q4 24 | $250.2M | $147.7M | ||
| Q3 24 | $91.3M | $98.5M | ||
| Q2 24 | $82.8M | $96.5M | ||
| Q1 24 | $-15.9M | $87.6M |
| Q4 25 | $155.4M | $48.2M | ||
| Q3 25 | $33.4M | $100.1M | ||
| Q2 25 | $-114.7M | $177.9M | ||
| Q1 25 | $932.0K | $51.5M | ||
| Q4 24 | $225.4M | $94.1M | ||
| Q3 24 | $64.8M | $71.8M | ||
| Q2 24 | $71.4M | $74.0M | ||
| Q1 24 | $-32.1M | $65.5M |
| Q4 25 | 19.5% | 6.2% | ||
| Q3 25 | 4.7% | 14.2% | ||
| Q2 25 | -17.2% | 27.4% | ||
| Q1 25 | 0.2% | 9.1% | ||
| Q4 24 | 39.3% | 15.7% | ||
| Q3 24 | 11.9% | 13.2% | ||
| Q2 24 | 14.2% | 15.1% | ||
| Q1 24 | -7.0% | 14.8% |
| Q4 25 | 7.8% | 17.2% | ||
| Q3 25 | 3.7% | 3.6% | ||
| Q2 25 | 3.4% | 2.9% | ||
| Q1 25 | 4.1% | 2.2% | ||
| Q4 24 | 4.3% | 9.0% | ||
| Q3 24 | 4.9% | 4.9% | ||
| Q2 24 | 2.2% | 4.6% | ||
| Q1 24 | 3.5% | 5.0% |
| Q4 25 | 79.14× | 1.80× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | -2.54× | 8.73× | ||
| Q1 25 | 0.29× | 1.80× | ||
| Q4 24 | 1.84× | 1.47× | ||
| Q3 24 | 1.36× | 1.27× | ||
| Q2 24 | 2.03× | 0.51× | ||
| Q1 24 | -0.12× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXON
| Software And Sensors Segment | $342.5M | 43% |
| TASER Devices Professional | $264.2M | 33% |
| Personal Sensors | $109.1M | 14% |
| Platform Solutions | $80.9M | 10% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
